POTIGA
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTIGA (POTIGA).
Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.
| Metabolism | Primarily glucuronidation by UGT1A9 and UGT2B7; minor CYP2E1 involvement. |
| Excretion | Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route. |
| Half-life | Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours). |
| Protein binding | Approximately 40% bound to albumin, mainly to albumin with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.7 L/kg, indicating distribution into total body water, and is consistent with low tissue binding. |
| Bioavailability | Oral bioavailability is approximately 90% (due to high absorption with minimal first-pass effect). |
| Onset of Action | Oral administration: Peak plasma concentrations are achieved in 1-2 hours, with clinical antiepileptic effect typically observed within 1-2 weeks of starting therapy (titration period). |
| Duration of Action | Duration of action approximately 12 hours (consistent with twice-daily dosing). Steady-state is achieved within 5-7 days. Clinical effect is sustained with regular dosing. |
| Molecular Weight | 302.33 |
100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.
| Dosage form | TABLET |
| Renal impairment | For CrCl 30-79 mL/min: 50 mg once daily for 1 week, then 100 mg twice daily; for CrCl 15-29 mL/min: 50 mg once daily for 1 week, then 50 mg twice daily; for CrCl <15 mL/min or hemodialysis: 50 mg once daily with post-dialysis supplementation of 50 mg. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily for 1 week, then 100 mg twice daily; Child-Pugh C: not recommended. |
| Pediatric use | For children ≥4 years with partial-onset seizures: 1.5 mg/kg/day (maximum 50 mg/day) orally once daily for 1 week, then increase to 3 mg/kg/day (or 100 mg/day) in 2 divided doses for week 2, followed by 4.5 mg/kg/day (or 150 mg/day) in 2 divided doses for week 3, then maintenance of 6 mg/kg/day (or 200 mg/day) in 2 divided doses. |
| Geriatric use | Start at 50 mg once daily for 1 week, then increase to 50 mg twice daily; consider lower doses due to age-related renal impairment; monitor renal function. |
| 1st trimester | POTIGA (ezogabine) is not recommended in first trimester due to potential teratogenic effects; animal studies have shown fetal harm. Avoid unless benefit clearly outweighs risk. |
| 2nd trimester | Use in second trimester only if essential; limited data but potential for adverse fetal effects persists. Monitor fetal growth. |
| 3rd trimester | In third trimester, risk of neonatal withdrawal or sedation; avoid use near term unless necessary. Consider gradual withdrawal before delivery. |
Clinical note
Comprehensive clinical and safety monograph for POTIGA (POTIGA).
| Placental transfer | Ezogabine crosses the placenta in animal studies; human data limited but transfer is expected due to molecular weight and lipophilicity. Fetal plasma concentrations may be similar to maternal. |
| Breastfeeding | Ezogabine is excreted in breast milk; breastfeeding is not recommended due to risk of infant sedation, poor feeding, and potential neurodevelopmental effects. If use is unavoidable, monitor infant for drowsiness and weight gain. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester: potential for major malformations, but data insufficient. Second and third trimesters: risk of fetal toxicity and neonatal withdrawal. Should only be used if benefit outweighs risk. |
| Fetal Monitoring | Monitor fetal growth and development via ultrasound during pregnancy. Assess neonatal for signs of withdrawal (irritability, feeding difficulties) and respiratory depression after delivery. Therapeutic drug monitoring in mother may be considered due to pregnancy-induced pharmacokinetic changes. |
| Fertility Effects | No specific human studies; animal studies show no significant impairment of fertility. However, hormonal contraception efficacy may be reduced due to potential enzyme induction; advise alternative or additional non-hormonal contraception. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ezogabine or any excipientHistory of retinal pigment abnormalities or vision loss due to previous ezogabine useConcomitant use with other potassium channel openers
| Precautions | Neuropsychiatric symptoms (hallucinations, confusion, psychosis), Increased risk of suicidal thoughts/behavior, QT prolongation (dose-dependent), Urinary retention, PR interval prolongation, Hepatotoxicity |
| Food/Dietary | No significant food interactions reported. Take with or without food. Avoid alcohol and grapefruit juice as they may exacerbate CNS effects or affect metabolism. |
| Clinical Pearls | Potiga (ezogabine/retigabine) is a neuronal potassium channel opener indicated as adjunctive treatment for partial-onset seizures. Requires ophthalmic monitoring due to risk of retinal pigment changes (blue-gray discoloration) and potential visual field defects. Urothelial effects (urinary retention, dysuria) are common; assess baseline renal function. QT prolongation possible; avoid with other QT-prolonging drugs. Titrate slowly to minimize CNS effects (dizziness, somnolence, ataxia). |
| Patient Advice | Take exactly as prescribed; do not abruptly stop therapy. · May cause dizziness or drowsiness; avoid driving until effects known. · Report any vision changes, eye pain, or blue-gray discoloration of skin/nails/retina. · Report difficulty urinating or blood in urine immediately. · Avoid alcohol and other CNS depressants. · Use effective contraception if applicable (can reduce hormonal contraceptive efficacy). · Store at room temperature (68-77°F) in original container. · Do not double dose if missed; contact doctor for missed dose instructions. |
Loading safety data…